CC
Post# of 153887
(Total Views: 604)
Posted On: 06/02/2020 4:15:07 PM
I am optimistic too, but there was one moment when I got a bit shocked. I believe I heard Dr. JL say it is time that we finsih the P2 so we can start - get on to P3.
"Treating thousand" - could also mean a P3 with a cohort of 3 000.
Biggest challenge for the future according to Dr. JL enough supply - quick enough.
NP: mentioned preparing documents for govenrment funding to pay for the studies. Was the question asked in relation to studies for CoVid or in general?
Anyway, the rest of the information given adds up to well orchestrated symphony so to speak.
- Submit data to the FDA early July
- publish available data so the meds know we are getting results
- look for a distribution partner
- prepare for uplisting (contact with the exchange, secure backing of an investment banking institution)
- secure supplies
Samsumg Bilologics
When NP and SK excerised their warrants I was speculating that Samsung had put the gun to CYDY's head. Either pay or wait for delivery 6 months after you settled your debt. We need to plan our production for the coming 3 or 6 months - what do you want CYDY?
Seems like that was spot on, as NP now stated that they are fully paid up with SBio.
Could be that the reason why we "only" get 120.000 dosis in early July has again to do with:
- NP did not have more cash on hand to pay for more upfront
- SBio did not have higher production capacity short term
- SBio did assign a very low credit limit due to the limited funds the company has
If the latter is the case this could become a revolving issue until we get the funding questions settled.
Greetings from Germany
baggo-mh
"Treating thousand" - could also mean a P3 with a cohort of 3 000.
Biggest challenge for the future according to Dr. JL enough supply - quick enough.
NP: mentioned preparing documents for govenrment funding to pay for the studies. Was the question asked in relation to studies for CoVid or in general?
Anyway, the rest of the information given adds up to well orchestrated symphony so to speak.
- Submit data to the FDA early July
- publish available data so the meds know we are getting results
- look for a distribution partner
- prepare for uplisting (contact with the exchange, secure backing of an investment banking institution)
- secure supplies
Samsumg Bilologics
When NP and SK excerised their warrants I was speculating that Samsung had put the gun to CYDY's head. Either pay or wait for delivery 6 months after you settled your debt. We need to plan our production for the coming 3 or 6 months - what do you want CYDY?
Seems like that was spot on, as NP now stated that they are fully paid up with SBio.
Could be that the reason why we "only" get 120.000 dosis in early July has again to do with:
- NP did not have more cash on hand to pay for more upfront
- SBio did not have higher production capacity short term
- SBio did assign a very low credit limit due to the limited funds the company has
If the latter is the case this could become a revolving issue until we get the funding questions settled.
Greetings from Germany
baggo-mh
(2)
(0)